Clinician Information
Clinician Information
Information about Chemosaturation, how to refer and treatment follow-ups for Clinicians.
For patients with liver cancer, current options for treatment include chemotherapy that is delivered through the patient’s whole body (systemic chemotherapy), surgery, or loco regional therapies, such as ablation, embolisation, or radiation therapy.
The CHEMOSAT® system may complement these current treatment strategies, offering hope for patients who may otherwise have limited treatment options.
The vascular isolation of the liver from the systemic circulation allows much higher doses of melphalan to be delivered with improved outcomes and reduced systemic toxicities to almost negligible levels.
CHEMOSAT® delivers chemotherapy to the entire liver targeting microscopic and macroscopic metastases distributed throughout the liver, which are often undetectable radiologically and unsuitable for surgical resection.
The procedure typically takes approximately three to four hours to complete and involves a core multidisciplinary team including a medical oncologist, interventional radiologist, anaesthetist, and perfusionist. A pharmacist is also required to dispense the melphalan, while an intensivist or critical care team will be required post procedure.
CHEMOSAT® now has an established presence in several countries with more than twenty-two cancer centres globally and over five hundred procedures performed. The team at Southampton (UK) have performed over 200 treatments in over eighty patients to date.
